• Gut microbiota composition during a 12-week intervention with delayed-release dimethyl fumarate in multiple sclerosis – a pilot trial 

      Larsen, Christopher Storm; Myhr, Kjell-Morten; Farbu, Elisabeth; Midgard, Rune; Nyquist, Kaja Beate; Broch, Line; Berg-Hansen, Pål; Buness, A.; Holm, Kristian; Ueland, Thor; Fallang, Lars-Egil; Burum-Auensen, Espen; Hov, Johannes Espolin Roksund; Holmøy, Trygve (Peer reviewed; Journal article, 2019)
      Introduction: Patients with multiple sclerosis may have a distinct gut microbiota profile. Delayed-release dimethyl fumarate is an orally administered drug for relapsing-remitting multiple sclerosis, which has been associated ...
    • Respiratory dysfunction three months after severe COVID-19 is associated with gut microbiota alterations 

      Vestad, Beate; Ueland, Thor; Lerum, Tøri Vigeland; Dahl, Tuva Børresdatter; Holm, Kristian; Barratt-Due, Andreas; Kåsine, Trine; Dyrhol-Riise, Anne Ma; Stiksrud, Birgitte; Tonby, Kristian; Hoel, Hedda; Olsen, Inge Christoffer; Henriksen, Katerina N.; Tveita, Anders Aune; Manotheepan, Ravinea; Haugli, Mette; Eiken, Ragnhild; Berg, Åse; Halvorsen, Bente; Lekva, Tove; Ranheim, Trine; Michelsen, Annika Elisabeth; Kildal, Anders Benjamin; Johannessen, Asgeir; Thoresen, Lars; Skudal, Hilde Kristin; Kittang, Bård Reiakvam; Olsen, Roy Bjørkholt; Ystrøm, Carl Magnus; Skei, Nina Vibeche; Hannula, Raisa; Aballi, Saad; Kvåle, Reidar; Skjønsberg, Ole Henning; Aukrust, Pål; Hov, Johannes Espolin Roksund; Trøseid, Marius (Peer reviewed; Journal article, 2022)
      Background: Although coronavirus disease 2019 (COVID-19) is primarily a respiratory infection, mounting evidence suggests that the gastrointestinal (GI) tract is involved in the disease, with gut barrier dysfunction and ...